OBJECTIVE: To determine whether a microsatellite polymorphism located towards the 3 H H end of the low density lipoprotein receptor gene (LDLR) is associated with obesity. DESIGN: A cross-sectional case-control study. SUBJECTS: One hundred and seven obese individuals, de®ned as a body mass index (BMI) ! ! 26 kg/m 2 , and 163 lean individuals, de®ned as a BMI`26 kg/m 2 . MEASUREMENTS: BMI, blood pressure, serum lipids, alleles of LDLR microsatellite (106 bp, 108 bp and 112 bp). RESULTS: There was a signi®cant association between variants of the LDLR microsatellite and obesity, in the overall tested population, due to a contributing effect in females (w w 2 5 12.3, P 5 0.002), but not in males (w w 2 5 0.3, P 5 0.87). In females, individuals with the 106 bp allele were more likely to be lean, while individuals with the 112 bp and/or 108 bp alleles tended to be obese. CONCLUSIONS: These results suggest that in females, LDLR may play a role in the development of obesity.
Introduction
Obesity is a common disorder affecting approximately 3 in 10 adult Caucasians. Obesity has been shown to be more prevalent in patients with type II diabetes, hypertension and hyperlipidaemia and carries an increased risk of cardiovascular event. 1 The origins of obesity have not been completely identi®ed but studies have illustrated a strong polygenic tendency. 2 Studies by Despre Âs et al 3 have shown that lipoprotein concentration in blood is proportional to abdominal fat deposition in obese individuals. Consequently, defects in lipoprotein receptors may be involved in obesity.
The low density lipoprotein (LDL) receptor is involved in regulating plasma LDL concentration and hence cholesterol and plasma lipids in the blood. Polymorphisms in the LDL receptor gene (LDLR) have been implicated in familial hypercholesterolaemia, 4 a disorder affecting 1 in 500 individuals and characterized by very high blood cholesterol. The gene encoding the LDL receptor, LDLR, is at chromosome 19p13.2 and is linked to the insulin receptor locus. LDLR has been implicated in obesity in hypertensives and has been linked to the atherogenic lipoprotein phenotype.
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The positive association results for obesity in essential hypertensives involved ApaLl 6 and Hincll 7 polymorphisms of LDLR. These studies indicated that there was no association of the LDLR polymorphisms with hypertension, but when the hypertensives were divided into lean and obese categories, an association was observed between both polymorphisms and obesity. Although the ApaLl and Hincll polymorphisms are located towards the 5 H end of LDLR, all variants in LDLR display strong linkage disequilibrium. Both of these showed an association with obesity in essential hypertensives but not with obesity in normotensives. In contrast, a recent preliminary study 8 using a small number of normotensives, suggested that there may be an association with obesity of an LDLR microsatellite variant, located towards the 3 H end of the gene in exon 18. 9 To determine whether there is an association of this polymorphism with obesity, lean and obese populations were genotyped in the present study for the LDLR microsatellite which involves variation in an AT repeat sequence.
Methods

Subjects
Approval for all research preformed in this study was granted by Grif®th University's Ethics Committee for Experimentation on Humans. Blood (10 ml) was collected from the antecubital fossa of obese and lean subjects and placed in a lithium heparin tube. All individuals donating blood samples gave informed consent and were adult Caucasians of British descent, living in Australia. Since these subjects are predominantly British derived Caucasians whose ancestors emigrated from a range of locations within the British Isles within the last 160 y, they are unlikely to suffer from local aggregation of genetic traits, as has been noted for discrete regional populations within the UK. Individuals were recruited primarily from volunteers involved in the Nambour Skin Cancer trial, and also from general practitioners and from media releases. After completion of a questionnaire, all subjects were screened to ensure individuals were unrelated and those with a family history of diabetes or thyroid disease were excluded. Recruited individuals were then divided into lean and obese categories on the basis of body mass index (BMI), as previously described. 6, 8, 10 One hundred and seven obese and 163 lean individuals were classi®ed as obese if their BMI ! 26 kg/m 2 or as lean if their BMI`26 kg/m 2 . Since previous studies had shown an association of LDLR with obesity in hypertensives, individuals were also classi®ed on the basis of measured blood pressure as normotensives and hypertensives, as previously described. 7, 11 For the purposes of this study, individuals were classi®ed as hypertensive if, prior to medication, they had a blood pressure ! 140/90 mmHg, were at the same time of blood sampling receiving antihypertensive medication, and were the offspring of two hypertensive parents. Normotensives had a blood pressure`140/90 mmHg. Individuals were classi®ed as predisposed normotensives (110 subjects) if the normotensive status of their parents, who were aged b 50 y, was also established.
Lipid Analysis
Blood being used in the study was transported on ice to the laboratory. The blood sample was centrifuged at 3800 rpm for 10 min to separate the blood cells from the plasma. Blood and buffy coats were stored at 770 C prior to DNA extraction. Plasma was analysed for total cholesterol, high density lipoprotein cholesterol (HDL-cholesterol) and triglyceride. Cholesterol was analysed on a BM Hitachi 747-200 analyser using the CHOD-PAP enzymatic colorimetric method. 12 HDL-cholesterol was precipitated with polyethylene glycol. Triglyceride was assayed on the same analyser using the GPO-PAP enzymatic colorimetric method. 13 
Genetic Analysis
DNA was extracted using a standard salting out method 14 and then genotyped for the LDLR microsatellite polymorphism. The LDLR polymorphism was ampli®ed using primers, GZ-7 and GZ-8, 9 in the polymerase chain reaction (PCR). The GZ-7 primer was labelled with the FAM¯uorescent dye (Applied Biosystems, Foster City, CA, USA). PCR ampli®ca-tion involved ®nal concentrations of 200 mM dNTPs, 1.75 mM MgCl 2 , reaction buffer (50 mM KCl, 10 mM Tris-HCl, pH 9.0, 0.1% Triton), 1.2 units of Taq polymerase (Perkin-Elmer, Norwalk, CT, USA) and 150 ng puri®ed DNA. PCR ampli®cations were performed using an initial 94 C denaturing period of 4 min, followed by 35 cycles of 94 C for 40 s; 60 C for 90 s and a ®nal extension of 72 C for 120 s as previously published. 8 Detection of PCR products involved electrophoresis on a 6% polyacrylamide denaturing gel and analysis using the Applied Biosystems 373 DNA sequencer with Genescan software.
Statistical Analysis
Differences in total cholesterol, triglyceride, HDLcholesterol, LDL-cholesterol and very low density lipoprotein cholesterol (VLDL-cholesterol) as compared to BMI and genotype were determined by covariance and one-way analysis of variance (ANOVA). Chi-squared analysis was used to determine differences between allele frequencies in obese and lean populations. Allele frequencies were also tested using a chi-squared approach, but with Monte Carlo simulations, to test for signi®cant differences. 15 A Monte Carlo approach was used to overcome statistical analysis dif®culties such as analysing low cell numbers when using a multi-allele microsatellite variant. 15 
Results
Following PCR using FAM labelled primers that detect the LDLR AT dinucleotide repeat polymorphism, Genescan analysis was used to identify fragment sizes for three alleles of 106 bp, 108 bp and 112 bp sizes. A combination of these alleles resulted in homozygous or heterozygous genotypes.
The results of the study on 107 obese subjects (those with a BMI ! 26 kg/m 2 ) and 163 lean subjects (those with a BMI`26 kg/m 2 ) are shown in Table 1 . Chi-squared analysis on the total allele counts revealed a signi®cant difference (w 2 7.6, P 0.023) between the lean and obese groups. This was con®rmed by Monte Carlo analysis with 5000 simulations, (w 2 7.6, P 0.027). When the obese and lean groups were divided into males and females, there was a signi®cant difference between the lean and obese populations in females (w 2 12.3, P 0.0002; Monte Carlo P 0.003, n 5000) but not in males (w 2 0.3, P 0.87; Monte Carlo P 0.87, n 10 000) ( Table 1) .
To determine whether this association was independent of hypertension, individuals were subgrouped according to blood pressure status, giving 77 hypertensives and 110 predisposed normotensives (Table  2) . No association between hypertension and polymorphisms in the LDLR microsatellite marker was found (w 2 1.6, P 0.44; Monte Carlo P 0.47, n 5000). Furthermore there was no signi®cant difference between frequencies of lean and obese nor-motensives (w 2 1.3, P 0.53; Monte Carlo P 0.55, n 5000) (Table 3) although there was a signi®cant difference between frequencies of lean and obese hypertensives (w 2 9.5, P 0.009; Monte Carlo P 0.009, n 5000) ( Table 4 ) which has been shown previously. 7 Further subdivision of obese and lean normotensives by gender did however show a signi®cant difference between the lean and obese populations in females (w 2 7.2, P 0.028; Monte Carlo P 0.027, n 5000) but not males (w 2 1.1, P 0.58; Monte Carlo P 0.62, n 5000) (Table 3) . Similarly, subdivision of obese and lean hypertensives by gender, also showed a signi®cant difference between the lean and obese populations in females (w 2 7.4, P 0.025; Monte Carlo P 0.032, n 5000) but not males (w 2 3.1, P 0.21; Monte Carlo P 0.22, n 5000) ( Table 4) .
Genotypic analysis performed on the complete sample population (Table 1) indicated that individuals with the 106 bp allele were more likely to be lean, compared to individuals possessing 108 bp or 112 bp alleles. This situation applied to the female population but not to the male population. Genotypes in the three populations were therefore classi®ed as 106 bp homozygotes, 106 bp heterozygotes and the other allele combinations. The results when chi-squared analysis was performed in the total obese and lean population as well as in females and males are illustrated in Table  5 . Results from Table 5 indicated that there was a signi®cant association of LDLR genotype with obesity in the complete sample population (w 2 9.2, P 0.01; Monte Carlo P 0.01, n 5000) and in the female population (w 2 13.0, P 0.002; Monte Carlo P 0.001, n 5000) but not in the male population (w 2 4.5, P 0.10; Monte Carlo P 0.12, n 5000). All tested populations were shown to be in Hardy- Weinberg equilibrium for the polymorphism. From these results, females who did not possess a 106 bp allele were 2.7 times more likely to be obese. Similarly, one way analysis of variance (ANOVA) of BMI performed on the three different allele combinations ( Figure 1 ) illustrated that there was a signi®cant difference between the 106 bp homozygotes and the other allele combinations in the combined sample population (P 0.023) as well as in the female population (P 0.003), but not in the male population (P 0.083).
One way analysis of variance was also used to investigate differences in lipid levels in the lean and obese populations. The results of the one-way ANOVA study comparing the relationship between the plasma lipid concentrations and BMI (Table 6 ) revealed a signi®cant difference between LDL-cholesterol concentrations and BMI, as well as LDLR genotype and BMI, in females and the combined sample population. In males, as well as in the combined sample population, a signi®cant difference between total cholesterol, triglyceride levels and VLDL-cholesterol levels was seen. There was no signi®cant relationship between HDL-cholesterol concentrations and BMI in the male and female population, but a highly signi®cant difference in the combined sample population. Covariant analysis on plasma lipids by LDLR genotype with BMI revealed that LDLR genotype has no capacity to predict circulating lipid concentrations (P 0.987), but rather to predict BMI (P 0.022). Therefore, LDLR genotype only predicts plasma lipids via its relationship with BMI.
Discussion
Genotypic analysis has been utilised in the present cross-sectional study to examine a microsatellite polymorphism of LDLR in relation to obesity. The LDL receptor is responsible for regulating plasma LDL concentrations and hence cholesterol and plasma lipids in the blood and gene defects in LDLR may impede such regulation. Since lipoprotein concentration in the blood is proportional to abdominal fat deposition in obese individuals, 3 LDLR was tested as a candidate gene for association with obesity.
We found an association of the LDLR polymorphism with obesity (P 0.023). This effect was contributed entirely by females in the study group *w 2 9.5, P 0.009; **w 2 7.4, P 0.025; ***w 2 3.1, P 0.21. (P 0.002) since males showed no association (P 0.87). Moreover, the result was not due to the in¯uence of hypertension on obesity, since a signi®-cant association was also observed in normotensive females, (P 0.28) but not in normotensive males (P 0.58).
ANOVA and chi-squared analysis on BMI values for allele combinations (Figure 1 ) revealed that female 106 bp homozygotes were more likely to be lean and women without a 106 bp allele were more likely to be obese. Hence, there is more than one speci®c genotype of this marker that is associated with obesity in females. ANOVA between the lean and obese individuals ( Table 6 ) also revealed that the LDLR genotype determines BMI. Therefore, a higher triglyceride, total cholesterol, LDL-cholesterol, VLDL-cholesterol and a lower HDL-cholesterol are a consequence of increased BMI. The association of LDLR variants and obesity therefore appears to be related to the inheritance of the 106 bp allele.
Our study therefore suggests a possible obesity effect of LDLR in females. This may be the result of small numbers in the male population studied. There were only 116 males separated into 55 obese and 61 lean, and 154 females with 52 obese and 102 lean females in each category. Hence there are signi®-cantly more lean numbers tested in the female populations. Further studies undertaken on larger overall populations may determine whether the detected association is in fact con®ned to females alone. Variation in LDLR could in¯uence fat deposition in females since both the ANOVA and chi-squared analysis on BMI values revealed that those without the 106 bp allele were more likely to be obese. It is possible that LDLR may also play an important obesity role in males but that the current tested population was too small to detect signi®cant differences. However, other studies have found signi®cant involvement of b3-adrenergic receptor genes in female, but not male, obesity. 16 The study on the b3-adrenergic receptor showed that there is a difference in fat distribution in the sexes, with men tending to have a higher intraabdominal and lower peripheral fat mass than women. These gender differences in fat distribution may arise because obesity in¯uences sexual maturation in girls, which may arise through a b3-adrenergic receptor effect directly on the hypothalamus. LDLR may also affect obesity development in maturing females, with females who do not possess a 106 bp allele of the tested LDLR variant being predisposed to being obese.
In previous studies, the 5 H end of LDLR has been implicated in obesity in essential hypertensives. 6, 7 In the present study, the signi®cant association of obesity with LDLR microsatellite variants was independent of hypertension, since a signi®cant difference was also illustrated in the female normotensive sub-population. It is not, however, clear from such data whether the association is with obesity or some other facet of Syndrome X', although we were able to exclude hypertension. For example, LDLR has been linked to the atherogenic lipoprotein phenotype 5 which is more prevalent in obese individuals. Also, the present results do not exclude the possibility of a primary association with a genetic variant in a gene in linkage disequilibrium with variation at the LDLR locus. Thus, although the present results represent important suggestive evidence, much more work will be needed to establish a mechanistic relationship between the associated polymorphism and a functional variant(s) in or near the LDLR gene.
